Biosyntia in biotin deal

Danish biotech Biosyntia has signed a contract with Germany’s Wacker Group to develop a large-scale production process for fermentation-based biotin based on Biosyntia’s technology

The two companies aim for the material to be available “for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative”. It is currently only produced synthetically from petrochemicals.

Also known as vitamin B7, biotin is a coenzyme for the metabolism of proteins, fats and carbohydrates. Personal care is among its uses, though the largest is food and beverages. It also finds applications in infant nutrition, nutraceuticals, pet food, animal feed and pharmaceuticals. The market has reportedly been growing at 10% year and is expected to reach $376 million in 2026.

Biosyntia has a proprietary microbial technology platform, on which it is building a rapidly growing pipeline of active ingredients for the beauty and nutrition industries. Wacker, meanwhile, brings expertise in biotechnological process development and industrial-scale fermentation, which it already uses to produce L-cysteine.

Latest Issues

Connex-C Asia 2025

Lee Kong Chian School of Medicine - Ong Tiong Tat and Irene Tan Liang Kheng Auditorium 11 Mandalay Road, Level 4, Singapore 308232
31 July - 1 August 2025

Breakthrough Science & Claims Testing - The SCS Annual Conference

Royal College of Surgeons of England, London
2 - 3 July